Drugs / Sodium Phenylacetate and Sodium Benzoate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00597909 | Dec 2007 → Sep 2008 | hepatic encephalopathy | Amgen | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium Phenylacetate and Sodium Benzoate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00597909 ↗ |
| Route | Intravenous | “5.5 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose” NCT00597909 ↗ |